VEGFA and renal cell carcinoma: The new era of modern therapeutic options for RCC was initiated in 2006, with the approval of sunitinib, a pioneer tyrosine kinase inhibitor (TKI) targeting VEGF to avoid the metastatic state in RCC (mRCC).